FindTrial
Sign In

Perioperative treatment patterns and outcomes by risk of recurrence for patients with HER2-positive early breast cancer; A retrospective database study in Japan

Perioperative treatment patterns and outcomes by risk of recurrence for patients with HER2-positive early breast cancer; A retrospective database study in Japan - HER2 eBC DB Study

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000061730
Enrollment
Unknown
Registered
2026-05-30
Start date
2026-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER2 positive breast cancer

Interventions

None listed

Sponsors

Daiichi Sankyo Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Patients newly diagnosed with breast cancer between 1 October 2018 and 30 September 2024 2.Aged 18 years or older at the date of breast cancer diagnosis 3.Patients with breast cancer in clinical stage I to III 4.Patients with HER2-positive breast cancer 5. Underwent curative surgery for breast cancer during the period from the date of breast cancer diagnosis until 30 September 2024

Exclusion criteria

Exclusion criteria: 1.Has a history of diagnosis of cancer other than breast cancer prior to the diagnosis of breast cancer

Design outcomes

Primary

MeasureTime frame
To use a database to assess the implementation and efficacy of perioperative treatment for HER2-positive breast cancer patients stratified by disease stage—

Countries

Japan

Contacts

Public ContactTakayuki Ezumi

Daiichi Sankyo Co., Ltd. Medical Evidence Department

contact_for_DSMA_JP@daiichisankyo.com03-6225-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026